Laekna Inc

Laekna Inc operates with a current ratio of 5.54, indicating strong short-term liquidity, and a debt-to-equity ratio of 0.1, suggesting a conservative capital structure with limited leverage. However, the company reported negative operating and free cash flows of -92.82 million CNY and -224.93 million CNY, respectively, signaling cash flow challenges. The company's total equity of 1,180.36 million CNY is significantly higher than its total liabilities of 234.47 million CNY, supporting its liquidity position. The company's profitability metrics are weak, with a return on equity of -19.43% and a return on assets of -16.21%, both well below the industry median for biotechnology firms. Gross profit of 86.42 million CNY on revenue of 106.72 million CNY suggests a high gross margin, but this is offset by a significant operating loss of -225.44 million CNY. The negative net income of -229.32 million CNY further underscores the company's current unprofitability. Laekna Inc's revenue is not segmented by geographic region or product line in the available data, making it difficult to assess geographic or product concentration risk. The absence of disclosed revenue segments limits the ability to evaluate diversification or exposure to specific markets. The company's growth trajectory is uncertain, with no specific revenue growth or decline figures provided for the current or next fiscal year. The negative operating and free cash flows suggest that the company is not currently generating sufficient cash to fund operations or expansion. Analysts have assigned a mean price target of 24.89 CNY, with a median of 24.16 CNY, and a mean recommendation of 1.50, indicating a generally positive outlook despite the company's current financial performance. The risk assessment highlights medium liquidity risk and low dilution risk, with a key flag indicating that net cash is negative after subtracting total debt. The company's capital expenditures of -1.06 million CNY are minimal, suggesting limited investment in physical assets. The absence of disclosed dilution sources or recent equity issuance events implies that the company is not currently under pressure to raise additional capital. No recent events, such as filings or transcripts, are provided in the available data to inform the company's strategic direction or operational developments. The lack of recent disclosures limits the ability to assess the company's response to market conditions or regulatory changes.